Plozasiran, an RNA Interference Agent Targeting APOC3, for …
May 28, 2024 · We carried out a 48-week, phase 2b, double-blind, randomized, placebo-controlled trial evaluating the safety and efficacy of plozasiran, a hepatocyte-targeted APOC3 …
Plozasiran: What is it and is it FDA approved? - Drugs.com
Nov 18, 2024 · Plozasiran is a first-in-class investigational RNA interference (RNAi) therapeutic in development for the treatment of familial chylomicronemia syndrome.
Plozasiran for Managing Persistent Chylomicronemia and …
Sep 2, 2024 · Plozasiran is a small interfering RNA that reduces hepatic production of apolipoprotein C-III and circulating triglycerides. In a phase 3 trial, we randomly assigned 75 …
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia: The
Jul 1, 2024 · Objective: To determine the tolerability, efficacy, and dose of plozasiran, an APOC3-targeted small interfering-RNA (siRNA) drug, for lowering triglyceride and apolipoprotein C3 …
Plozasiran, an RNA Interference Agent Targeting APOC3, for …
Sep 12, 2024 · In this randomized, controlled trial involving participants with mixed hyperlipidemia, plozasiran, as compared with placebo, significantly reduced triglyceride levels at 24 weeks. A …
Arrowhead Pharmaceuticals Presents New Data at AHA24 from …
Nov 16, 2024 · Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 …
Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy …
Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of apolipoprotein C-III (APOC3) which is a …
Arrowhead Pharmaceuticals Announces Acceptance of New Drug …
1 day ago · About Plozasiran. Plozasiran, previously called ARO-APOC3, is a first-in-class investigational RNA interference (RNAi) therapeutic designed to reduce production of …
Plozasiran Reduces Triglyceride Levels by 74% at 24 Weeks
Apr 7, 2024 · In patients with severely elevated triglyceride levels at risk for developing acute pancreatitis, the investigational drug plozasiran reduced triglyceride levels by an average of …
Plozasiran (ARO-APOC3) for Severe Hypertriglyceridemia
Objective To determine the tolerability, efficacy, and dose of plozasiran, an APOC3-targeted small interfering–RNA (siRNA) drug, for lowering triglyceride and apolipoprotein C3 (APOC3, …